Our Approach
Our proprietary, highly targeted antibody drug conjugates (ADCs) are armed with highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.
Pipeline
The selective targeting and unique mechanism of action of our ADCs enables the potential for our robust pipeline of therapies to have enhanced, durable efficacy and limited side effects in patients.
Clinical Trials
We are advancing our ADCs through clinical trials in multiple hematological and solid tumor indications, including a pivotal Phase II trial of ADCT-402 (loncastuximab tesirine) in patients with relapsed or refractory diffuse large B-cell lymphoma.
News
ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual Meeting
6 November 2019
ADC Therapeutics Announces Presentations at 61st American Society of Hematology (ASH) Annual MeetingPresentations highlight lead product candidate ADCT-402 as a single agent and in combination with checkpoint inhibitor durvalumab for relapsed or refractory B-cell non-Hodgkin lymphomas Updated interim data from pivotal Phase 2 clinical trial of ADCT-402 selected for oral presentation Company to host investor event on Sunday, December 8 Lausanne, Switzerland, November 6, 2019 –
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer
5 November 2019
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial OfficerBiopharma leader with deep oncology product launch experience will spearhead global commercial strategy and execution for ADCT-402 Lausanne, Switzerland, November 5, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors, today announced the appointment
ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer Research
4 November 2019
ADC Therapeutics Announces Publication of ADCT-402 Data in Clinical Cancer ResearchData support potential of ADCT-402 to become an important treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma Lausanne, Switzerland, November 4, 2019 – ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid
